TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study in Nature Communications linked higher blood levels of the gut-produced molecule imidazole propionate, or ImP, with Alzheimer’s-related biological markers and faster cognitive decline. Mouse experiments also found that ImP reaching the brain increased abnormal amyloid and tau accumulation, but the findings do not establish that the molecule causes Alzheimer’s in people or show that lowering it prevents disease.
Researchers report that imidazole propionate (ImP), a molecule produced by some gut bacteria, was linked to Alzheimer’s-related brain changes in mice and to biological markers and faster cognitive decline among people followed in a Wisconsin research cohort. The study, published in Nature Communications, identifies ImP as a possible research target, but does not show that it causes Alzheimer’s disease in people or that reducing it would prevent dementia.
The University of Wisconsin-Madison-led team studied ImP, which certain gut bacteria produce while using histidine, an amino acid found in many foods. ImP levels vary between people. The researchers say bacteria capable of producing it are found in many people, although they are not abundant in most. The molecule can enter the bloodstream after being made in the gut.
In mouse experiments, the researchers found that ImP reaching the brain increased the accumulation of abnormal beta amyloid and tau proteins. These proteins are associated with Alzheimer’s disease, but results in mice do not establish that the same process causes disease in humans. The team also analyzed blood samples from almost 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies run through the Wisconsin Alzheimer’s Disease Research Center.
Among those participants, higher blood ImP concentrations were associated with biological markers linked to abnormal proteins and impaired neuron function. The researchers also compared blood levels with cognitive tests taken over time and reported faster decline among people with the highest ImP levels. The study describes an association in this human sample, not proof that ImP caused the decline. About 43% of participants carried a genetic variation associated with substantially higher ImP in blood; the researchers suspect it may affect how efficiently the kidneys clear the molecule.
A Possible Target Beyond Diet
The findings give researchers a specific molecule to investigate in the broader study of links between the gut and the brain. If further work confirms that ImP contributes to harmful changes, a treatment that lowers circulating levels could become a potential way to affect risk or disease progression. The present study, however, does not test such a treatment or establish that lowering ImP would improve outcomes.
The researchers cautioned against treating the result as a reason to cut out particular foods. Because gut bacteria produce ImP while using histidine, and histidine is an essential amino acid present in many foods, reducing dietary histidine is not a simple or established approach. The proposed direction is to investigate ways to lower ImP itself, but no ImP-lowering drug or prevention strategy is shown in this report.
As an affiliate, we earn on qualifying purchases.
From Gut Microbes to ImP
The work follows nearly a decade of research by University of Wisconsin-Madison professors Barbara Bendlin and Federico Rey into differences in gut microorganisms between people with Alzheimer’s disease and healthy people. Their earlier work raised the question of how those differences might relate to the brain. The new study focuses on one possible link: a bacterial product that can circulate beyond the intestines.
ImP has previously been linked in research to type 2 diabetes and coronary artery disease, according to the report. The new findings extend the question to brain health; they do not establish that the compound has the same role in those conditions or in dementia. Researchers from the University of California, Los Angeles, and the University of Gothenburg also contributed. The study received support from the Wisconsin Partnership Program, the National Institutes of Health and the U.S. Department of Agriculture.
“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”
— Barbara Bendlin, University of Wisconsin-Madison professor of medicine
Cause and Treatment Remain Unproven
The human findings show that higher ImP levels occurred alongside Alzheimer’s-related markers and faster cognitive decline; they do not establish cause and effect. The report does not state that participants were assigned to interventions that changed ImP, nor does it show that reducing the molecule changes brain markers or cognitive outcomes. The mouse findings offer experimental evidence about possible effects in animals, but their relevance to human disease needs further study.
The researchers suspect the genetic variation may influence kidney removal of ImP, but that explanation remains a proposed mechanism. The report also does not establish how much of a person’s ImP comes from particular bacteria, how levels change over time, or whether any safe and effective method exists to lower them. The association should not be taken as a diagnosis or as evidence that an individual’s diet or gut bacteria determine their Alzheimer’s risk.
Testing ImP as a Treatment Target
The next research question is whether ImP directly contributes to disease-related changes in people and whether lowering its blood concentration can alter those changes. Studies would need to examine that possibility before ImP could be considered a prevention or treatment target. The researchers’ proposed strategy is to look for an inhibitor that reduces ImP, rather than trying to remove histidine from the diet.
No clinical trial, drug, or expected treatment timeline is identified in the report. For now, the result is a lead for further investigation, not a basis for changing diet or medical care. The key next evidence would be research that tests the molecule’s role and evaluates whether a targeted reduction produces measurable benefits.
Key Questions
What is imidazole propionate?
Imidazole propionate, or ImP, is a molecule produced by certain gut bacteria as they use histidine, an amino acid. It can enter the bloodstream from the gut.
Does the study prove ImP causes Alzheimer’s disease?
No. The human results show an association between higher blood ImP, Alzheimer’s-related markers and faster cognitive decline. The mouse experiments found changes in amyloid and tau, but the study does not prove that ImP causes Alzheimer’s in people.
Should people avoid foods containing histidine?
The researchers do not recommend eliminating such foods. Histidine is an essential amino acid found in many foods, and the report says reducing it through diet is not a straightforward strategy.
Could lowering ImP prevent dementia?
That is a possibility the researchers want to investigate, not a demonstrated benefit. The study did not test an ImP-lowering treatment or show that reducing the molecule prevents dementia.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
